PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32277270-11 2021 Changes in acute PPG were significantly associated with changes in fasting plasma glucose (FPG) [per 10% change in PPG: beta = 0.085 (95% CI 0.003, 0.167), k = 14], but not with fasting insulin [beta = 1.20 (95% CI - 0.32, 2.71), k = 12]. ppg 17-20 insulin Homo sapiens 186-193 33730337-1 2021 INTRODUCTION: Basal-bolus (BB) and premixed insulin regimens may lower fasting plasma glucose (FPG) and postprandial plasma glucose (PPG), but are complex to use and associated with weight gain and hypoglycaemia. ppg 133-136 insulin Homo sapiens 44-51 30466191-4 2019 RESULTS: A statistically significant treatment difference in favour of fast-acting insulin aspart vs. insulin aspart was observed for the change in PPG increment at all post-meal time points (from 1 to 4 h) for those in the > 20 units bolus insulin subgroup. ppg 148-151 insulin Homo sapiens 83-90 33786271-1 2021 Background: In general, basal insulin targets fasting plasma glucose (FPG) levels, and prandial insulin targets postprandial glucose (PPG) levels. ppg 134-137 insulin Homo sapiens 96-103 33786271-2 2021 However, the effects of basal insulin on PPG levels are controversial. ppg 41-44 insulin Homo sapiens 30-37 31226281-3 2019 OBJECTIVES: To evaluate how often patients on insulin therapy measure PPG and modify insulin doses accordantly. ppg 70-73 insulin Homo sapiens 46-53 30466191-4 2019 RESULTS: A statistically significant treatment difference in favour of fast-acting insulin aspart vs. insulin aspart was observed for the change in PPG increment at all post-meal time points (from 1 to 4 h) for those in the > 20 units bolus insulin subgroup. ppg 148-151 insulin Homo sapiens 102-109 30466191-4 2019 RESULTS: A statistically significant treatment difference in favour of fast-acting insulin aspart vs. insulin aspart was observed for the change in PPG increment at all post-meal time points (from 1 to 4 h) for those in the > 20 units bolus insulin subgroup. ppg 148-151 insulin Homo sapiens 102-109 30466191-6 2019 CONCLUSION: Fast-acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin-resistant Type 2 diabetes. ppg 131-134 insulin Homo sapiens 24-31 28117542-13 2017 CONCLUSION: Applying an additional dose of insulin in dual wave bolus for high-protein mixed meal improved PPG. ppg 107-110 insulin Homo sapiens 43-50 29493118-1 2018 AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp). ppg 74-77 insulin Homo sapiens 120-127 29493118-1 2018 AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp). ppg 74-77 insulin Homo sapiens 161-168 25066229-2 2015 The relative contribution of postprandial plasma glucose (PPG) to overall HbA1c is estimated at 40-60%, with the effect of PPG on HbA1c being prominent in patients on basal insulin. ppg 123-126 insulin Homo sapiens 173-180 27986406-12 2017 CONCLUSIONS: Lixisenatide in combination with basal insulin was shown to be an effective treatment strategy for patients with type 2 diabetes, controlling HbA1c levels by reduction of PPG excursions during the whole day. ppg 184-187 insulin Homo sapiens 52-59 29032696-6 2017 Appropriately timed exposure of the liver to insulin is critical in suppressing hepatic glucose output (and therefore PPG levels) after a meal. ppg 118-121 insulin Homo sapiens 45-52 18667139-5 2007 Subsequently, a progressive loss of first-phase insulin response occurs, which is manifested by progressively increasing postprandial glucose (PPG) levels. ppg 143-146 insulin Homo sapiens 48-55 16526817-8 2006 Treating PPG with glinides improves IMT as well as interleukin-6 and C-reactive protein levels, while treating PPG with rapid-acting insulin analogues is also associated with improvements in endothelial dysfunction. ppg 111-114 insulin Homo sapiens 133-140 16919548-2 2006 After a meal, the rise in postprandial glucose (PPG) is controlled by the rapid pancreatic release of insulin, stimulated by both glucose and the intestinal production of the incretins glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1. ppg 48-51 insulin Homo sapiens 102-109 35598134-8 2022 About 73.5% of the respondents believed controlling fasting plasma glucose (FPG) level alone would not adequately control postprandial plasma glucose (PPG) level, and 93.0% of them preferred an insulin therapy at the initiation that controls both FPG and PPG levels. ppg 255-258 insulin Homo sapiens 194-201 35593434-8 2022 Indeed, in pivotal phase 3 trials, URLi was superior to Lispro for PPG control both at 1 hour and 2 hours after a meal in type 1 and type 2 diabetes with multiple daily injections and in type 1 diabetes with continuous subcutaneous insulin infusion. ppg 67-70 insulin Homo sapiens 232-239 33776458-8 2021 Conclusion: The analysis indicates that the supplementation of BOT with a single daily injection of prandial insulin is safe and effective for reducing HbA1c and PPG levels in patients with a high BeAM value (more than 50 mg/dl). ppg 162-165 insulin Homo sapiens 109-116 34150441-3 2021 The aim of this study was to define the differences in the efficacy of these two insulin analogues on PPG. ppg 102-105 insulin Homo sapiens 81-88 35598134-9 2022 CONCLUSION: Limited consultation time, high-carbohydrate diet, and a need for choosing insulin regimens that provide control for both PPG and FPG levels are some ground realities of DM management in India. ppg 134-137 insulin Homo sapiens 87-94 35044568-2 2022 The aim of this study was to compare PPG increments in Asian versus non-Asian adults with type 2 diabetes (T2D), who were insulin-naive or insulin-experienced, from the phase 3 insulin degludec/insulin aspart (IDegAsp) clinical trials. ppg 37-40 insulin Homo sapiens 122-129 35044568-2 2022 The aim of this study was to compare PPG increments in Asian versus non-Asian adults with type 2 diabetes (T2D), who were insulin-naive or insulin-experienced, from the phase 3 insulin degludec/insulin aspart (IDegAsp) clinical trials. ppg 37-40 insulin Homo sapiens 139-146 35044568-2 2022 The aim of this study was to compare PPG increments in Asian versus non-Asian adults with type 2 diabetes (T2D), who were insulin-naive or insulin-experienced, from the phase 3 insulin degludec/insulin aspart (IDegAsp) clinical trials. ppg 37-40 insulin Homo sapiens 177-184 35044568-2 2022 The aim of this study was to compare PPG increments in Asian versus non-Asian adults with type 2 diabetes (T2D), who were insulin-naive or insulin-experienced, from the phase 3 insulin degludec/insulin aspart (IDegAsp) clinical trials. ppg 37-40 insulin Homo sapiens 194-201